Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan’s Eisai Co.’s experimental Alzheimer’s disease medicines as it seeks to add treatments for brain disorders.
Teva Pharmaceutical Industries Ltd. is using records from its 24-hour support hotline in the U.S. to persuade thousands of multiple sclerosis patients to switch from its biggest-selling drug, Copaxone, to a new version that has patent protection until 2030.
Actavis Plc, the world’s second- largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs.
Pfizer Inc., Eli Lilly & Co. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
Teva Pharmaceutical Industries Ltd. failed to win backing from the European Union drug regulator for a new pill to treat multiple sclerosis, hurting the company’s effort to introduce a successor to its best-selling injection Copaxone.